BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16157308)

  • 1. Study of the peptide length and amino acid specific substitution in the antigenic activity of the chimeric synthetic peptides, containing the p19 core and gp46 envelope proteins of the HTLV-I virus.
    Marin MH; Rodríguez-Tanty C; Higginson-Clarke D; Bocalandro YM; Peña LP
    Biochem Biophys Res Commun; 2005 Oct; 336(3):983-6. PubMed ID: 16157308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigenicity of chimeric synthetic peptides based on HTLV-1 antigens and the impact of epitope orientation.
    Hernández M; Selles ME; Pozo Peña L; Gómez I; Melchor A
    Biochem Biophys Res Commun; 2000 Oct; 276(3):1085-8. PubMed ID: 11027594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric synthetic peptides containing two immunodominant epitopes from the envelope gp46 and the transmembrane gp21 glycoproteins of HTLV-I virus.
    Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
    Biochem Biophys Res Commun; 2001 Nov; 289(1):1-6. PubMed ID: 11708767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric synthetic peptides from the envelope (gp46) and the transmembrane (gp21) glycoproteins for the detection of antibodies to human T-cell leukemia virus type II.
    Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
    Biochem Biophys Res Commun; 2001 Nov; 289(1):7-12. PubMed ID: 11708768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of a chimeric synthetic peptide from the core p19 protein and the envelope gp46 glycoprotein in the immunodiagnosis of HTLV-II virus infection.
    Hernández Marin M; Márquez Bocalandro Y; Vallejo RV; Rodríguez Tanty C; Higginson Clark D; Pozo Peña L; Silva León C
    Prep Biochem Biotechnol; 2003 Feb; 33(1):29-38. PubMed ID: 12693813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of amino acid substitutions on antigenicity of immunodominant regions of the HTLV type I envelope surface gylcoprotein: a study using monoclonal antibodies raised against relevant peptides.
    Londos-Gagliardi D; Jauvin V; Armengaut MH; Astier-Gin T; Goetz M; Huet S; Guillemain BJ
    AIDS Res Hum Retroviruses; 1999 Jul; 15(10):909-20. PubMed ID: 10408728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and conformational properties of an N-linked glycosylated peptide epitope of human T-lymphotropic virus type 1 (HTLV-I).
    Conrad SF; Byeon IJ; DiGeorge AM; Lairmore MD; Tsai MD; Kaumaya PT
    Biomed Pept Proteins Nucleic Acids; 1995; 1(2):83-92. PubMed ID: 9346859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Evaluation of a Novel ELISA for Detection of Antibodies against HTLV-I Using Chimeric Peptides.
    Mosadeghi P; Heydari-Zarnagh H
    Iran J Allergy Asthma Immunol; 2018 Apr; 17(2):144-150. PubMed ID: 29757587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46.
    Palker TJ; Tanner ME; Scearce RM; Streilein RD; Clark ME; Haynes BF
    J Immunol; 1989 Feb; 142(3):971-8. PubMed ID: 2563272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine.
    Baba E; Nakamura M; Tanaka Y; Kuroki M; Itoyama Y; Nakano S; Niho Y
    J Immunol; 1993 Jul; 151(2):1013-24. PubMed ID: 7687611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cervicovaginal synthesis of IgG antibodies to the immunodominant 175-199 domain of the surface glycoprotein gp46 of human T-cell leukemia virus type I.
    Bélec L; Georges-Courbot MC; Georges A; Mohamed AS; Londos-Gagliardi D; Hallouin MC; Hocini H; Guillemain B
    J Med Virol; 1996 Sep; 50(1):42-9. PubMed ID: 8890040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Identification of immunoreactive epitopes in proteins coded by gag, env, and pol genes of the type I human T-lymphotropic virus (HTLV-I) using synthetic peptides].
    Iaroslavtseva NG; Ivanov VS; Grebennikova ZhO; Kornilaeva GV; Pashkova TA; Chikin LD; Ostrovskiĭ AG; Andreev SM; Khaitov RM; Karamov EV
    Bioorg Khim; 1995 Oct; 21(10):752-60. PubMed ID: 8573207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1.
    Kuroki M; Nakamura M; Itoyama Y; Tanaka Y; Shiraki H; Baba E; Esaki T; Tatsumoto T; Nagafuchi S; Nakano S
    J Immunol; 1992 Aug; 149(3):940-8. PubMed ID: 1378869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cross reactivity and amino acid structural homology of immunodominant peptide fragments of structural viruses from the human retroviruses HTLV-I, HTLV-II, HIV-1, and HIV-2].
    Rasuli AM; Rasuli ShM; Klepikov NN; Andreev SM; Meshcheriakova DV; Tarasova SO; Seniuta NB; Syrtsev AV; Gurtsevich VE
    Mol Biol (Mosk); 1995; 29(1):225-38. PubMed ID: 7723762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of HTLV-1-specific CTL directed against synthetic and naturally processed peptides in HLA-B*3501 transgenic mice.
    Schönbach C; Nokihara K; Bangham CR; Kariyone A; Karaki S; Shida H; Takatsu K; Egawa K; Wiesmüller KH; Takiguchi M
    Virology; 1996 Dec; 226(1):102-12. PubMed ID: 8941327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization.
    Tanaka Y; Zeng L; Shiraki H; Shida H; Tozawa H
    J Immunol; 1991 Jul; 147(1):354-60. PubMed ID: 1711082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of immunodominant epitopes of human T-lymphotropic virus type 1 (HTLV-I) using synthetic peptides.
    Lairmore MD; Lal RB; Kaumaya PT
    Biomed Pept Proteins Nucleic Acids; 1995; 1(3):117-22. PubMed ID: 9346842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequence variations in the amino- and carboxy-terminal parts of the surface envelope glycoprotein of HTLV type 1 induce specific neutralizing antibodies.
    Tallet B; Astier-Gin T; Moynet D; Londos-Gagliardi D; Guillemain B
    AIDS Res Hum Retroviruses; 2001 Mar; 17(4):337-48. PubMed ID: 11242520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition by human sera of a variable region of the surface glycoprotein of HTLV-I.
    Edouard E; Londos-Gagliardi D; Busetta B; Geoffre S; Dalbon P; Moreau JP; Guillemain B
    Leukemia; 1994 Apr; 8 Suppl 1():S65-7. PubMed ID: 8152306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of monoclonal antibodies directed against the gp46 of human T-cell leukemia virus type I.
    Edouard E; Legrand E; Astier-Gin T; Dalibart R; Geoffre S; Dalbon P; Guillemain B; Londos-Gagliardi D
    Leukemia; 1994 Apr; 8 Suppl 1():S60-4. PubMed ID: 7512182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.